|Mr. Peter S. Greenleaf M.B.A.||Pres, CEO & Director||1.06M||N/A||1970|
|Dr. Erik R. Eglite J.D., M.B.A., D.P.M.||Sr. VP, Gen. Counsel & Chief Corp. Compliance Officer||527.42k||N/A||1965|
|Mr. Dennis Bourgeault CPA, C.A.||Advisor||396.35k||N/A||N/A|
|Dr. Neil Solomons M.D.||Chief Medical Officer||548.85k||N/A||N/A|
|Mr. Matthew Maxwell Donley M.B.A.||Exec. VP of Internal Operations & Strategy||544.83k||N/A||1969|
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of December 8, 2019 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 10.